申请人:F. HOFFMANN-LA ROCHE AG
公开号:EP0787493A1
公开(公告)日:1997-08-06
The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula
wherein
Ais aryl
R1is hydrogen, hydroxy, lower alkyl, lower alkoxy, R-CO- or R-COO-, wherein R is lower alkyl;
R2is hydrogen, lower alkyl or cycloalkyl
R3-R7are hydrogen, lower alkyl, lower alkoxy, hydroxy or
R3 and R4taken together are -(CH2)n- or
R6 and R7taken together are -OCH2O- and
nis 3 or 4,
as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.
本发明涉及通式四氢异喹啉衍生物的用途
其中
A为芳基
R1 是氢、羟基、低级烷基、低级烷氧基、R-CO- 或 R-COO-,其中 R 是低级烷基;
R2 是氢、低级烷基或环烷基
R3-R7 为氢、低级烷基、低级烷氧基、羟基,或
R3 和 R4 合在一起为-(CH2)n- 或
R6 和 R7 合在一起是 -OCH2O- 且
n 为 3 或 4、
以及药学上可接受的盐类,用于制造控制或治疗疾病的药物,这些疾病是 NMDA 受体亚型特异性阻断剂的治疗适应症。